NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

No patients in this trial was given extra doses beyond their own set of doses made for the purposes of this trial. The set of doses for all randomized patients were between a minimum of five and a maximum of ten, depending upon how many doses could be made from the tumor material obtained.

So if you were a treatment patient, you would have received between 5 and ten doses, depending, of course, on the length of survival.

And if you were a control patient, you would have received up to the same upon cross over, depending again on your length of survival.

This trial does not offer a "single dose" or "rescue dose".

You've cited the clinical site on numerous occasions. Instead of simply reading the name of the trial, consider scrolling down a bit and looking at the injection schedule for both arms:

Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
https://clinicaltrials.gov/ct2/show/NCT00045968?cond=dcvax-L&draw=2&rank=3